Prashant Bhangui, Eric Vibert, Pietro Majno, Chady Salloum, Paola Andreani, Joao Zocrato, Philippe Ichai, Faouzi Saliba, Rene Adam, Denis Castaing, Daniel Azoulay – 11 February 2011 – For patients who have cirrhosis with hepatocellular carcinoma (HCC), living donor liver transplantation (LDLT) reduces waiting time and dropout rates. We performed a comparative intention‐to‐treat analysis of recurrence rates and survival outcomes after LDLT and deceased donor liver transplantation (DDLT) in HCC patients.

Luca Di Tommaso, Annarita Destro, Valentina Fabbris, Gaia Spagnuolo, Anna Laura Fracanzani, Silvia Fargion, Marco Maggioni, Carlo Patriarca, Roberto Maria Macchi, Michela Quagliuolo, Mauro Borzio, Massimo Iavarone, Angelo Sangiovanni, Massimo Colombo, Massimo Roncalli – 10 February 2011 – The American Association for the Study of Liver Diseases guidelines recommend the use of all available markers for improving the accuracy of the diagnosis of small hepatocellular carcinoma (HCC).

Jung Min Lee, Sang Hoon Ahn, Hyon Suk Kim, Hana Park, Hye Young Chang, Do Young Kim, Seong Gyu Hwang, Kyu Sung Rim, Chae Yoon Chon, Kwang‐Hyub Han, Jun Yong Park – 10 February 2011 – Quantitative hepatitis B surface antigen (qHBsAg) and quantitative hepatitis B e antigen (qHBeAg) titers are emerging as useful tools for measuring viral loads and for predicting the virological response (VR) and serological response (SR) to pegylated interferon therapy. However, the clinical utility of these assays in patients taking entecavir (ETV) is largely unknown.

Byoung Kwon Yoo, Prasanna K. Santhekadur, Rachel Gredler, Dong Chen, Luni Emdad, Sujit Bhutia, Lewis Pannell, Paul B. Fisher, Devanand Sarkar – 10 February 2011 – There is virtually no effective treatment for advanced hepatocellular carcinoma (HCC) and novel targets need to be identified to develop effective treatment. We recently documented that the oncogene Astrocyte elevated gene‐1 (AEG‐1) plays a seminal role in hepatocarcinogenesis.

Daniel Hartmann, Ujala Srivastava, Michaela Thaler, Karin N. Kleinhans, Gisèle N'Kontchou, Annika Scheffold, Kerstin Bauer, Ramona F. Kratzer, Natalia Kloos, Sarah‐Fee Katz, Zhangfa Song, Yvonne Begus‐Nahrmann, Alexander Kleger, Guido von Figura, Pavel Strnad, André Lechel, Cagatay Günes, Andrej Potthoff, Katja Deterding, Heiner Wedemeyer, Zhenyu Ju, Ge Song, Feng Xiao, Sonja Gillen, Hubert Schrezenmeier, Thomas Mertens, Marianne Ziol, Helmut Friess, Michael Jarek, Michael P. Manns, Michel Beaugrand, K.

Yong‐Ning Xin, Zhong‐Hua Lin, An‐Jin Chen, Shi‐Ying Xuan – 10 February 2011

Laura Lorenzon, Vincenzo Ziparo – 10 February 2011

Sandeep M. Patel, Seth Sweetser – 10 February 2011

Cristiano Quintini, Giuseppe D'Amico, Chase Brown, Federico Aucejo, Koji Hashimoto, Dympna M. Kelly, Bijan Eghtesad, Mark Sands, John J. Fung, Charles M. Miller – 4 February 2011 – Refractory ascites (RA) is a challenging complication after orthotopic liver transplantation. Its treatment consists of the removal of the precipitating factors. When the etiology is unknown, supportive treatment can be attempted. In severe cases, transjugular intrahepatic portosystemic shunts, portocaval shunts, and liver retransplantation have been used with marginal results.

Andrew King, Gail Masterton, Bridget Gunson, Simon Olliff, Doris Redhead, Kamarjit Mangat, Gabriel Oniscu, Peter Hayes, Dhiraj Tripathi – 4 February 2011 – The role of transjugular intrahepatic portosystemic shunt (TIPS) insertion in managing the complications of portal hypertension is well established, but its utility in patients who have previously undergone liver transplantation is not well documented. Twenty‐two orthotopic liver transplantation (OLT) patients and 44 nontransplant patients (matched controls) who underwent TIPS were analyzed.